Amalgam Rx announced a $20 million credit investment from Catalio Capital Management to expand its Medical-Grade AI solutions for healthcare.
The senior secured loan provides an initial $12 million to support market growth and refinance debt, while giving Amalgam access to Catalio’s network of life sciences experts for strategic guidance.
Amalgam’s AI platform, developed over five years with strong safeguards, is designed to meet high clinical, ethical, and regulatory standards as AI adoption in healthcare accelerates.
Support: Amalgam’s financial advisor was KOI Capital Group, represented by Nemphos Braue. Catalio was represented by Covington & Burling.
KEY QUOTES:
“Our investment in Amalgam reflects Catalio’s commitment to backing the next generation of pioneering healthcare companies. Amalgam’s proven track record, scalable platform, and vision for intelligent, personalized care position them as a leader in facilitating high quality care. We’re proud to support the company’s next phase of growth as they continue to drive innovation at the intersection of digital health and life sciences.”
Catalio’s Dr. Nicholas von Guionneau, who joins Amalgam’s Board of Directors as an Observer
“We’re excited to welcome Catalio as a strategic partner through its $20 million credit investment. Catalio’s deep expertise in healthcare and life sciences, combined with their expansive venture network, makes them an ideal partner as we scale. This funding will accelerate the development and deployment of our medical-grade AI platform – enhancing decision-making for both patients and providers – and advance our mission to transform chronic disease management through intelligent, personalized care.”
Ryan Sysko, Chief Executive Officer of Amalgam Rx
